Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of 8 weeks of
therapy with nebivolol in comparison to placebo in younger patients 18 - 54 years of age with
stage 1 or stage 2 essential hypertension.